Key result
Recombinant human soluble thrombomodulin effectively prevented disseminated intravascular coagulation independent of antithrombin III levels, whereas heparin was ineffective in rats with reduced ATIII.
Why the study?
Does recombinant human soluble thrombomodulin (rhs-TM) prevent DIC in a rat model with reduced ATIII levels compared to heparin?
Does recombinant human soluble thrombomodulin (rhs-TM) prevent DIC in a rat model with reduced ATIII levels compared to heparin?
rhs-TM effectively inhibits coagulation independent of ATIII levels in a rat model of DIC, unlike heparin which depends on ATIII levels.
Answers are grounded in this paper and cite their sources.
rhs-TM may offer ATIII-independent DIC control in models; leaves open human translation pending trials.
We reported that recombinant human soluble thrombomodulin (rhs-TM) is effective for disseminated intravascular coagulation (DIC) in vivo, in mice and rats. In the present work, we investigated the effects of decreased plasma antithrombin III (ATIII) levels on anticoagulant effects of rhs-TM, as compared to findings with heparin, of which effect is lowered by the decreased plasma ATIII levels in patients with DIC. Rat plasma ATIII levels decreased when we mixed plasma with anti-rat ATIII antibody and the potential of heparin to prolong APTT or PT was markedly diminished. The potential of rhs-TM to prolong APTT and PT was not affected. In rats injected with anti-rat ATIII antibody, plasma ATIII levels decreased immediately. When the rats were infused with tissue factor (TF), DIC was induced. At doses of rhs-TM and heparin which were equally effective at inhibiting the decrease in platelet count and fibrinogen level in control rats treated with TF, only rhs-TM remained effective in preventing DIC in rats with reduced ATIII levels. Heparin was not effective when administered to these rats with reduced ATIII levels. Therefore, rhs-TM effectively inhibits coagulation independent of ATIII levels, in contrast to heparin, which depends on the ATIII level.
No takes yet. Share an insight, caveat, or question.
Aoki et al. (1994) studied Disseminated intravascular coagulation (DIC) with decreased plasma antithrombin III (ATIII) levels. Recombinant human soluble thrombomodulin (rhs-TM) vs. Heparin was evaluated on Prevention of DIC (inhibition of decrease in platelet count and fibrinogen level). Recombinant human soluble thrombomodulin effectively prevented disseminated intravascular coagulation independent of antithrombin III levels, whereas heparin was ineffective in rats with reduced ATIII.
Synapse has enriched 10 related papers. Consider them for comparative context: